| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/15/2004 | US20040072314 Isolating and purifying therapeutic polypeptide using undulating solid support comprising polyethersulphone |
| 04/15/2004 | US20040072300 Comprises expression vector coding cytokines/immunoglobulin fusion protein for treating tumor and autoimmune disorders; immunotherapy; antitumor agents |
| 04/15/2004 | US20040072299 Multiple cytokine protein complexes |
| 04/15/2004 | US20040072290 Transgenic cells expressing anti-human squamous-cell carcinoma monoclonal antibody with enhanced antibody dependent cellular cytotoxicity (ADCC); drug targeting and delivery |
| 04/15/2004 | US20040072285 Induction of apoptosis and cell growth inhibition by protein 4.33 |
| 04/15/2004 | US20040072265 Using tumor antigen CDNA probes to diagnose and treat brain disorders; antiproliferative/antitumor agents |
| 04/15/2004 | US20040072264 Comprises nucleotide sequences coding ca protein (CAP) for diagnosing and treating cell proliferative disorders; antiproliferative agents |
| 04/15/2004 | US20040072258 Disruption of a Ras-protein complex by a Ras antagonist, e.g.,farensylthiosalicylic acid, analyzed; identifying drug candidates inhibiting aberrant Ras activity; binding andinactivating mRNA of anchor protein by a oligonucleotides |
| 04/15/2004 | US20040072256 Nk cells activiating receptors and their therapeutic and diagnostic uses |
| 04/15/2004 | US20040072240 Identifying cryptic epitopes comprising amino acid sequences of tumor antigen for diagnosis and treatment of viral and cancer disorder; viricides; antitumor agents |
| 04/15/2004 | US20040072238 Integrin binding polipeptide for diagnosis, prevention and treatment of renal failure, thrombosis, osteoporosis, cancers and diabetes |
| 04/15/2004 | US20040072189 Diagnosing cancer via presence of osteopontin in epithelial cells; genetic vaccines; antitumor agents |
| 04/15/2004 | US20040072188 Comprises nucleotide sequences coding B-cell activating factor receptor (BAFF-R) for diagnosis, prevention, treatment and/or delay of cancers, lymphomas and autoimmune diseases |
| 04/15/2004 | US20040072185 Cellular genes involved in oncogenesis, products of said genes and their diagnostic and therapeutic uses |
| 04/15/2004 | US20040072184 Cancer associated protein kinases and their uses |
| 04/15/2004 | US20040072177 Novel human serine-threonine kinase |
| 04/15/2004 | US20040072171 Screening for regulatory factors of neurofibromatosis (NF2); antitumor agents |
| 04/15/2004 | US20040072168 Novel deoxynucleoside kinase enzyme variants |
| 04/15/2004 | US20040072154 Novel compositions and methods for cancer |
| 04/15/2004 | US20040071774 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same |
| 04/15/2004 | US20040071712 Modified peptides as therapeutic agents |
| 04/15/2004 | US20040071711 Imaging, diagnosis and treatment of disease |
| 04/15/2004 | US20040071709 Corona-virus-like particles comprising functionally deleted genomes |
| 04/15/2004 | US20040071699 An antagonists, or agonists, producing antibodies, used as immunotherapy treating allergy, acquired immune deficiency syndrome, autoimmune diabetes, thyroiditis |
| 04/15/2004 | US20040071697 Reducing epithelial toxicity during cancer therapy |
| 04/15/2004 | US20040071692 Minimizes toxicity to normal tissue; high therapeutic index |
| 04/15/2004 | US20040071691 Including compatible solute; enhancing effectiveness of protein containing active material; reducing cytotoxic activity |
| 04/15/2004 | US20040071671 Cell therapy method for the treatment of tumors |
| 04/15/2004 | US20040071658 Vaccine immunotherapy for immune suppressed patients |
| 04/15/2004 | US20040071656 Modulation of heat-shock-protein-based immunotherapies |
| 04/15/2004 | US20040071655 Binding agent |
| 04/15/2004 | US20040069523 Use of Vitamin D-Derivatives in the Treatment of Osteoporosis and related bone disorders, as well as novel vitamin D3-Deviratives |
| 04/15/2004 | DE4325927B4 Taxol enthaltender Medikamentierungskit Taxol-containing Medikamentierungskit |
| 04/15/2004 | DE10246434A1 New N-(2-chloro-4-fluorobenzoyl)-N'-phenyl-urea derivatives, are glycogenolysis inhibitors useful e.g. for treating type II diabetes, arteriosclerosis, ischemia, angina pectoris or tumor diseases |
| 04/15/2004 | CA2500960A1 Therapeutic uspa1-derived peptides |
| 04/15/2004 | CA2500869A1 Spiro compounds, medicinal compositions containing the same and intermediates of the compounds |
| 04/15/2004 | CA2500833A1 Tumor targeting agents and uses thereof |
| 04/15/2004 | CA2500830A1 Tumor targeting agents and uses thereof |
| 04/15/2004 | CA2500827A1 Tumor targeting agents and uses thereof |
| 04/15/2004 | CA2500538A1 Method for treating or preventing metastasis of colorectal cancers |
| 04/15/2004 | CA2500531A1 Method for treating or preventing metastasis of colorectal cancers |
| 04/15/2004 | CA2500413A1 Method of strengthening foreign epitope presentation by mhc class i by inhibiting tap activity |
| 04/15/2004 | CA2500328A1 Use of cyclic depsipeptide as a chemotherapeutic agent against cancer |
| 04/15/2004 | CA2500151A1 Ttk protein kinase gene for diagnosing and treating non-small cell lung cancers |
| 04/15/2004 | CA2500056A1 Synthesis of oligomeric epicatechin and catechin-derived procyanidins |
| 04/15/2004 | CA2498829A1 Use of protein tyrosine phosphatase inhibitors for prevention and/or treatment of cancer |
| 04/15/2004 | CA2498555A1 Combination chemotherapy with dehydroequol and selected chemotherapeutic agents |
| 04/15/2004 | CA2498026A1 Compositions for treatment of prostate and other cancers |
| 04/14/2004 | EP1408119A1 Method of screening abc protein promoter/inhibitor |
| 04/14/2004 | EP1408112A1 MONOCLONAL ANTIBODY BINDING TO MT4−MMP CATALYTIC DOMAIN |
| 04/14/2004 | EP1408110A2 Oligonucleotide mediated specific cytokine induction and in vivo protection from infection |
| 04/14/2004 | EP1408106A1 Cancer immuno-therapy |
| 04/14/2004 | EP1408066A1 Block copolymer reduced in impurity content; polymeric carrier; pharmaceutical preparations in polymeric form and process for the preparation of the same |
| 04/14/2004 | EP1408043A1 2''oxo-voruscharin and analogues thereof |
| 04/14/2004 | EP1407784A1 Antitumor agents |
| 04/14/2004 | EP1407781A1 Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents |
| 04/14/2004 | EP1407771A1 Sophoridine and use thereof as an analgesic |
| 04/14/2004 | EP1407768A2 The potassium channel opener retigabine for the treatment of diseases |
| 04/14/2004 | EP1407269A2 A method for diagnosing a person having multiple sclerosis |
| 04/14/2004 | EP1407047A1 METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON GLUTATHIONE-S-TRANSFERASE Pi EXPRESSION |
| 04/14/2004 | EP1407044A2 Rna interference mediating small rna molecules |
| 04/14/2004 | EP1407033A1 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva) |
| 04/14/2004 | EP1407032A1 Anti-neoplastic viral agents |
| 04/14/2004 | EP1407019A2 Intestinal proteins |
| 04/14/2004 | EP1407015A2 Compositions and methods relating to breast specific genes and proteins |
| 04/14/2004 | EP1407010A1 Regulation of human aminopeptidase n |
| 04/14/2004 | EP1406998A2 Liver engrafting cells, assays, and uses thereof |
| 04/14/2004 | EP1406930A2 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| 04/14/2004 | EP1406928A1 Ntb-a, a surface molecule involved in natural killer cells activity |
| 04/14/2004 | EP1406926A2 Novel neurotrophic factors |
| 04/14/2004 | EP1406915A2 Antisense modulation of transforming growth factor beta receptor ii expression |
| 04/14/2004 | EP1406914A2 Porphyrin derivatives for photodynamic therapy |
| 04/14/2004 | EP1406910A1 Novel bisphosphonate derivatives, their preparation methods and uses |
| 04/14/2004 | EP1406907A1 New antitumoral derivatives of et-743 |
| 04/14/2004 | EP1406901A1 Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease |
| 04/14/2004 | EP1406899A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 04/14/2004 | EP1406895A1 Lactone formulations and method of use |
| 04/14/2004 | EP1406894A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 04/14/2004 | EP1406889A2 Interaction inhibitors of tcf-4 with beta-catenin |
| 04/14/2004 | EP1406879A1 Novel chelating agents and conjugates thereof, their synthesis and use as diagnostic and therapeutic agents |
| 04/14/2004 | EP1406878A1 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies |
| 04/14/2004 | EP1406876A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| 04/14/2004 | EP1406875A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 04/14/2004 | EP1406873A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 04/14/2004 | EP1406872A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 04/14/2004 | EP1406870A1 Taxol enhancer compounds |
| 04/14/2004 | EP1406869A1 Taxol enhancer compounds |
| 04/14/2004 | EP1406867A2 Thiolalkyl benzoic acid derivatives |
| 04/14/2004 | EP1406866A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 04/14/2004 | EP1406859A1 Substituted 4-aminocyclohexanol derivatives |
| 04/14/2004 | EP1406699A1 Antitumoral formulations of thioxanthenone |
| 04/14/2004 | EP1406698A2 Lipoxin analogs as novel inhibitors of angiogenesis |
| 04/14/2004 | EP1406668A1 Composite oncolytic herpes virus vectors |
| 04/14/2004 | EP1406667A2 METHODS FOR INCREASING i IN VIVO /i EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS |
| 04/14/2004 | EP1406664A2 Targeting chemical compounds to cells |
| 04/14/2004 | EP1406662A1 Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| 04/14/2004 | EP1406660A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
| 04/14/2004 | EP1406658A1 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan |
| 04/14/2004 | EP1406657A1 A novel engineered superantigen for human therapy |
| 04/14/2004 | EP1406656A2 METHODS OF ADMINISTERING ANTI-TNF$g(a) ANTIBODIES |